NCT01867333View on ClinicalTrials.gov

Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

August 12, 2013

Primary Completion Date

September 28, 2022

Study Completion Date

October 26, 2022

Conditions
Prostate Cancer
Interventions
BIOLOGICAL

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -F/TRICOM

A recombinant fowlpox virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.

BIOLOGICAL

PROSTVAC (rilimogene galvacirepvec/rilimogene glafolivec) -V/TRICOM

A recombinant vaccinia virus vector vaccine containing the genes for human prostate-specific antigen (PSA) and three co-stimulatory molecules.

BIOLOGICAL

Enzalutamide

An androgen receptor inhibitor.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01867333 - Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter